Cumulative incidence of nonrelapse mortality at 2 y according to grade of acute GVHD, type of donor, and hyperacute GVHD
Group . | Total no. of patients . | Acute GVHD grade II . | Acute GVHD grades III-IV . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No. of patients (%) . | % CI NRM . | HR . | 95% CI . | P . | No. of patients (%) . | % CI NRM . | HR . | 95% CI . | P . | ||
Mrel and no hyperacute | 109 | 61 (56) | 31 | 1.0 | Reference | — | 48 (44) | 58 | 1.0 | Reference | — |
Mrel and hyperacute | 28 | 19 (68) | 26 | 0.6 | 0.2-1.6 | .3 | 9 (32) | 33 | 0.8 | 0.25-2.7 | .8 |
MUD/MMrel and no hyperacute | 82 | 46 (56) | 35 | 1.1 | 0.6-2.1 | .8 | 36 (44) | 64 | 1.5 | 0.9-2.6 | .12 |
MUD/MMrel and hyperacute | 45 | 25 (56) | 54 | 1.5* | 0.8-3.0 | .2 | 20 (44) | 80 | 2.5† | 1.4-4.6 | .003 |
Overall | 264 | 151 (57) | 35 | — | — | — | 113 (43) | 62 | 2.8‡ | 1.9-3.9‡ | < .001‡ |
Group . | Total no. of patients . | Acute GVHD grade II . | Acute GVHD grades III-IV . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No. of patients (%) . | % CI NRM . | HR . | 95% CI . | P . | No. of patients (%) . | % CI NRM . | HR . | 95% CI . | P . | ||
Mrel and no hyperacute | 109 | 61 (56) | 31 | 1.0 | Reference | — | 48 (44) | 58 | 1.0 | Reference | — |
Mrel and hyperacute | 28 | 19 (68) | 26 | 0.6 | 0.2-1.6 | .3 | 9 (32) | 33 | 0.8 | 0.25-2.7 | .8 |
MUD/MMrel and no hyperacute | 82 | 46 (56) | 35 | 1.1 | 0.6-2.1 | .8 | 36 (44) | 64 | 1.5 | 0.9-2.6 | .12 |
MUD/MMrel and hyperacute | 45 | 25 (56) | 54 | 1.5* | 0.8-3.0 | .2 | 20 (44) | 80 | 2.5† | 1.4-4.6 | .003 |
Overall | 264 | 151 (57) | 35 | — | — | — | 113 (43) | 62 | 2.8‡ | 1.9-3.9‡ | < .001‡ |
% CI indicates percent cumulative incidence; NRM, nonrelapse mortality; —, not applicable.
Comparing MUD/MMrel and hyperacute to all other subgroups, HR (95% CI) is 1.6 (0.9-2.9) (P = .1).
Comparing MUD/MMrel and hyperacute to all other subgroups, HR (95% CI) is 2.2 (1.2-3.8) (P = .001).
Comparing NRM for overall grade II versus grades III-IV.